Why the study?
Is bivalirudin a feasible, safe, and cost-effective alternative to heparin for systemic anticoagulation in pediatric extracorporeal membrane oxygenation?
Is bivalirudin a feasible, safe, and cost-effective alternative to heparin for systemic anticoagulation in pediatric extracorporeal membrane oxygenation?
Bivalirudin appears to be a feasible, safe, and cost-effective alternative to heparin for systemic anticoagulation in pediatric ECMO, though randomized trials are needed for confirmation.
Bivalirudin may offer an alternative to heparin in pediatric ECMO; leaves open confirmation in randomized trials.
This study showed that the use of bivalirudin in pediatric extracorporeal membrane oxygenation support is feasible, safe, reliable, and cost-effective in comparison to heparin. Further prospective randomized clinical trials are necessary to confirm our observations.
No takes yet. Share an insight, caveat, or question.
Hamzah et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: